title: Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage.
abstract: BACKGROUND
  Visfatin, a proinflammatory mediator, has been associated with poor clinical outcomes after acute brain injury. The present study is designed to investigate the potential association between plasma visfatin levels and the risk of hematoma growth (HG) and early neurologic deterioration (END) after intracerebral hemorrhage.
  
  
  METHODS
  There were 85 patients as cases who presented with first-time hemorrhagic stroke that were assessed within 6h after the incident. The control group consisted of 85 healthy volunteers. HG was defined as hematoma enlargement >33% at 24h. END was defined as an increase of ≥ 4 points in National Institute of Health Stroke Scale score at 24h from symptoms onset. Plasma visfatin levels were determined using enzyme immunoassay.
  
  
  RESULTS
  Plasma visfatin levels were significantly higher in patients compared to controls. Plasma visfatin level emerged as an independent predictor of HG [odds ratio (OR), 1.154; 95% confidence interval (CI), 1.046-3.108; P=0.009] and END (OR, 1.195; 95% CI, 1.073-3.516; P=0.005). For predicting HG, area under curve (AUC) of plasma visfatin level (0.814; 95% CI: 0.715-0.890) was similar to that of hematoma volume (0.839; 95% CI, 0.743-0.909) (P=0.703). For predicting END, AUC of plasma visfatin level (0.828; 95% CI: 0.730-0.901) was similar to that of hematoma volume (0.863; 95% CI, 0.771-0.928) (P=0.605). Visfatin did not improve AUC of hematoma volume for predicting HG and END (both P>0.05).
  
  
  CONCLUSIONS
  Plasma visfatin level represents a novel biomarker for predicting HG and END.
authors.affiliation: Department of Neurosurgery, The first people's Hospital of Xiaoshan District of Hangzhou City, 199 Shixin South Road, Xiaoshan District, Hangzhou 311200, China.
authors.forename: Shui-Jun
authors.initials: SJ
authors.lastname: Gu
authors.forename: Hong-Fei
authors.initials: HF
authors.lastname: Xuan
authors.forename: Ming
authors.initials: M
authors.lastname: Lu
authors.forename: Xin-Zhi
authors.initials: XZ
authors.lastname: Chen
authors.forename: Wei-Feng
authors.initials: WF
authors.lastname: Dong
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Yan
authors.forename: Yun
authors.initials: Y
authors.lastname: Si
authors.forename: Guo-Liang
authors.initials: GL
authors.lastname: Gao
authors.forename: Dian-Xiang
authors.initials: DX
authors.lastname: Hu
authors.forename: Jian-Qing
authors.initials: JQ
authors.lastname: Miao
mesh_terms: D000368:Aged; D019540:Area Under Curve; D020145:Basal Ganglia Hemorrhage / Q000097:blood* / Q000175:diagnosis / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood*; D016022:Case-Control Studies; D060825:Cognitive Dysfunction / Q000097:blood* / Q000175:diagnosis / Q000503:physiopathology; D016207:Cytokines / Q000097:blood* / Q000235:genetics; D005260:Female; D015870:Gene Expression; D006406:Hematoma / Q000097:blood* / Q000175:diagnosis / Q000503:physiopathology; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood* / Q000235:genetics; D011379:Prognosis; D012372:ROC Curve; D013997:Time Factors
chemical_list: D015415:Biomarkers; D016207:Cytokines; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human
keywords: Biomarker; Early neurologic deterioration; Hematoma growth; Intracerebral hemorrhage; Visfatin